These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22320865)

  • 21. Effect of rapamycin treatment in human seminoma TCam-2 cells through inhibition of G1-S transition.
    Onel T; Erdogan CS; Aru B; Yildirim E; Demirel GY; Yaba A
    Naunyn Schmiedebergs Arch Pharmacol; 2023 May; 396(5):1009-1018. PubMed ID: 36598515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of AMPK by Telmisartan Decreases Basal and PDGF-stimulated VSMC Proliferation via Inhibiting the mTOR/p70S6K Signaling Axis.
    Hwang YJ; Park JH; Cho DH
    J Korean Med Sci; 2020 Sep; 35(35):e289. PubMed ID: 32893519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
    Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
    Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1.
    Wang YD; Su YJ; Li JY; Yao XC; Liang GJ
    Int J Clin Exp Pathol; 2015; 8(5):5182-8. PubMed ID: 26191215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.
    Ishikawa D; Takeuchi S; Nakagawa T; Sano T; Nakade J; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Nakamura T; Matsumoto K; Kagamu H; Yoshizawa H; Yano S
    PLoS One; 2013; 8(5):e62104. PubMed ID: 23690929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
    Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
    Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel semisynthetic inhibitor of the FRB domain of mammalian target of rapamycin blocks proliferation and triggers apoptosis in chemoresistant prostate cancer cells.
    Morad SA; Schmid M; Büchele B; Siehl HU; El Gafaary M; Lunov O; Syrovets T; Simmet T
    Mol Pharmacol; 2013 Feb; 83(2):531-41. PubMed ID: 23208958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
    Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL
    PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
    Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW
    Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.
    Gordeev SA; Bykova TV; Zubova SG; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
    Oncotarget; 2015 Dec; 6(42):44905-26. PubMed ID: 26636543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells.
    Spampatti M; Vlotides G; Spöttl G; Maurer J; Göke B; Auernhammer CJ
    World J Gastroenterol; 2014 Aug; 20(29):10038-49. PubMed ID: 25110431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapamycin and the inhibition of the secretory phenotype.
    Wang R; Sunchu B; Perez VI
    Exp Gerontol; 2017 Aug; 94():89-92. PubMed ID: 28167236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p70 S6K1 nuclear localization depends on its mTOR-mediated phosphorylation at T389, but not on its kinase activity towards S6.
    Rosner M; Schipany K; Hengstschläger M
    Amino Acids; 2012 Jun; 42(6):2251-6. PubMed ID: 21710263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro study of effects and mechanism of rapamycin-induced autophagy in keloid fibroblasts].
    Gao J; Jiao H; Cao R; Yang Z; Sun X; Zhuang Q; Xiao Z; Yan Z
    Zhonghua Zheng Xing Wai Ke Za Zhi; 2016 May; 32(3):208-14. PubMed ID: 30044067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice.
    Nishikawa T; Takaoka M; Ohara T; Tomono Y; Hao H; Bao X; Fukazawa T; Wang Z; Sakurama K; Fujiwara Y; Motoki T; Shirakawa Y; Yamatsuji T; Tanaka N; Fujiwara T; Naomoto Y
    Cancer Biol Ther; 2013 Mar; 14(3):230-6. PubMed ID: 23291985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
    Panwalkar A; Verstovsek S; Giles FJ
    Cancer; 2004 Feb; 100(4):657-66. PubMed ID: 14770419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitor.
    Syed F; Sherris D; Paus R; Varmeh S; Singh S; Pandolfi PP; Bayat A
    Am J Pathol; 2012 Nov; 181(5):1642-58. PubMed ID: 22982188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
    Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
    Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mammalian Target of Rapamycin (mTOR) Regulates Transforming Growth Factor-β1 (TGF-β1)-Induced Epithelial-Mesenchymal Transition via Decreased Pyruvate Kinase M2 (PKM2) Expression in Cervical Cancer Cells.
    Cheng KY; Hao M
    Med Sci Monit; 2017 Apr; 23():2017-2028. PubMed ID: 28446743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.